Sovaldi Reviewers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA staff that participated in the review of Gilead’s sofosbuvir for chronic hepatitis C.
You may also be interested in...
Sovaldi Clinical Development
A timeline chronicling the development of Gilead’s hepatitis C treatment sofosbuvir.
Better Late Than Never: “Breakthrough” Status Aided Sovaldi’s On-Time Approval
Although Gilead’s hepatitis C drug picked up the “breakthrough therapy” moniker with just two months left in the NDA review cycle, the designation enabled FDA staff to analyze new VALENCE and PHOTON-1 trial data and still approve sofosbuvir by the PDUFA goal date.
How Sovaldi Won A Broad Label: Emerging Data Swayed Reluctant FDA
Agency reviewers were skeptical about awarding Gilead’s sofosbuvir an indication for use in combination with other, unspecified agents for treating chronic hepatitis C – a game-changing approach for the fast-evolving field. However, data submitted late in the review process from two ongoing Phase III studies convinced FDA that a broad indication was justified.